In some instances, a single exposure to a strong stress cracking agent may cause premature failure, yet in others it may appear to have no effect after numerous applications. For treatment groups, a 0.5" (13 mm) square pre-soaked gauze pad containing the disinfectant/cleaner of choice was applied to the center portion of the test specimen, replacing the gauze pad every 24 hours for a total of 72 hours (3 applications). The Trilliant HC8910 and HC8920 materials were apparently unaffected by the application of Virex® TB and demonstrated nearly 100% retention of tensile properties relative to the strain control group.

Wall thickness should be as thin as possible for the application . Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application . You have the responsibility to conduct full-scale end-product performance testing to determine suitability in your application, and you assume all risk and liability arising from your use of the information and/or use or handling of any product .

The company adds value to global customers and improves sustainability through formulating materials, such as:

Vibrant colors in transparent and opaque options help set this line of high-temperature and high-performance formulations apart from other options.

These new materials are formulated to improve design, performance and processing capabilities versus traditional silicone, thermoplastic urethane (TPU), or thermoplastic vulcanizates.  

The company adds value to global customers and improves sustainability through formulating materials, such as:

The company adds value to global customers and improves sustainability through formulating materials, such as:

Veškeré časy nebo termíny dodání uvedené Prodávajícím (včetně těch, které jsou uvedeny v potvrzení objednávky) jsou pouze odhady a nelze je chápat jako podmínky prodeje.

 * Yes If ‘yes’, exact statement of the intent that is included in the facility’s TRA Plan to reduce the creation of the toxic substance at the facility: ** DEHA is a plasticizer and is created in our Orangeville Plasticizer plant (small quantities) and used as reactant in the formulation compound in our Orangeville compound site.   * For on­site use/processing Summarize why the toxic substance is used at the facility: ** DEHA is produced to be used for compound formulation. Materials or feedstock substitution Empty Product design or reformulation Empty Equipment or process modifications Empty Spill or leak prevention Empty On­site reuse, recycling or recovery Empty Improved inventory management or purchasing techniques Empty Good operator practice or training About us News Contact us Stay connected HEALTH healthycanadians.gc.ca TRAVEL travel.gc.ca SERVICE CANADA servicecanada.gc.ca JOBS jobbank.gc.ca ECONOMY actionplan.gc.ca Canada.gc.ca Terms and Conditions Transparency Version: 3.13.0 Empty Identify at least one reason why no option to reduce the use or creation of this substance was implemented at your facility: Select the applicable reason or reasons ** There are no alternative processes and/or equipment identified, New equipment and/or processes were investigated, however, deemed unfeasible Explanation of the reasons why no option will be implemented   Rationale for why the listed options were chosen for implementation   General description of any actions undertaken by the owner and operator of the facility to reduce the use and creation of the toxic substance at the facility that are outside of the plan   License Number of the toxic substance reduction planner who made recommendations in the toxic substance reduction plan for this substance (format TSRPXXXX): * TSRP0123 Name of the toxic substance reduction planner who made recommendations in the toxic substance reduction plan for this substance (First Name Last Name) Daryl Chartrand License Number of the toxic substance reduction planner who has certified the toxic substance reduction plan for this substance (format TSRPXXXX): * TSRP0123 Name of the toxic substance reduction planner who has certified the toxic substance reduction plan for this substance (First Name Last Name) Daryl Chartrand What version of the plan is this summary based on?

Additionally, Adjusted EPS excludes the impact of special items and amortization expense associated with intangible assets. 2 3 AVIENT OVERVIEW OUR VISION: Creating specialized and sustainable materials solutions that transform customer challenges into opportunities, bringing new products to life for a better world 2023 Financial ResultsCompany Overview Revenue By: 9,300 Employees 102 Manufacturing Sites 20,000+ Customers Key Highlights  Premier formulator of specialized and sustainable materials solutions  Asset-light business model, with flexibility to adapt to customer needs  Best-in-class technology and service (140+ PhDs / 2,500+ patents)  History of transformation through successful M&A while consistently returning cash to shareholders  Poised for continued future growth in excess of GDP $3.14B Revenue $2.36 Adjusted EPS $502M Adjusted EBITDA 16.0% Adjusted EBITDA Margins $186M Adjusted Free Cash Flow Over $1B in share buybacks since 2011 Raised dividend for 13 consecutive years, a 15% CAGR since 2011 U.S. & Canada EMEA Asia Latin America 64% 36% Specialty Engineered Materials Color Additives and Inks 41% 36% 18% 5% 7% 7% 23% 19% 9% 16% 10% 5% 4% Defense Healthcare Packaging Consumer Building & Construction Industrial Transportation Energy Telecom Geography Segment Industry 4 CRE AT ING A WORL D-CL AS S S US TAINABL E ORGANIZ AT ION 1. 6% annualized long term sales growth leveraging sustainable solutions, composites, healthcare and emerging regions 2. AS HIS H KHANDP UR P R E S I D E N T & C E O 7 8 PORTFOLIO TRANSFORMATION 8 7% 46% 66% 87% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2015 2020 2023 % o f A dj us te d E B IT D A Commodity JVs Distribution Performance Products & Solutions Specialty Businesses Adjusted EBITDA from Specialty Applications SUSTAINABILITY AS A GROWTH DRIVER 9 LONG-TERM REVENUE GROWTH DRIVERS Sustainable Solutions Composites, Healthcare, Asia / LATAM Overlap Other 60%+ Key Growth Drivers Total Company Revenue Growth Drivers Long-Term Growth Rate Sustainable Solutions 8–12% Composites 8–10% Healthcare 8–10% Asia / LATAM 5% Other 0–2% Avient 6% END MARKET OBSERVATIONS ( % O F C O M PA N Y S A L E S ) ENERGY 5% DEFENSE 7% TELECOMMUNICATIONS 4% HEALTHCARE 7% 10 TRANSPORTATION 10% INDUSTRIAL 16% BUILDING & CONSTRUCTION 9% CONSUMER 19% PACKAGING 23% 11 REGIONAL OBSERVATIONS ( % O F C O M PA N Y S A L E S ) 11 US & Canada Latin America EMEA Asia 41% 36% 18% 5% Q 4 2 0 2 3 R E S U L T S Q4 2023 PERFORMANCE VS. Further, as a result of Avient's portfolio shift to a pure play specialty formulator, it has completed several acquisitions and divestitures which have resulted in a significant amount of intangible asset amortization.